title: The mode of action of adenosine 3':5'-cyclic monophosphate in mammalian islets of Langerhans. Effects of insulin secretagogues on islet-cell protein kinase activity.
abstract: 1. Protein kinase activity was measured in islets of Langerhans that had been incubated in the presence of agents known to affect insulin release. 2. Glucagon, theophylline, caffeine and 3-isobutyl-1-methylxanthine, agents that raise cyclic AMP concentrations in islet cells and stimulate insulin release, increased protein kinase activity. Adrenaline and diazoxide, agents that decrease cyclic AMP concentrations and inhibit insulin secretion, decreased the activity. 3. The increase in protein kinase activity produced by different concentrations of 3-isobutyl-1-methylxanthine was apparently related to the increase in intracellular concentrations of cyclic AMP. 4. The sulphonylureas, tolbutamide and glibenclamide, agents that increase insulin release, also increased the protein kinase activity; however, leucine, arginine and xylitol, which also stimulate insulin release, were without effect on the kinase activity. 5. Increasing the glucose concentration of the incubation medium from 2 to 20mm had no effect on protein kinase activity. Further, the ability of 3-isobutyl-1-methylxanthine to increase the protein kinase activity was not affected by the glucose concentration of the incubation medium. 6. These results suggest that agents which affect insulin secretion by altering cyclic AMP concentrations may exert their effects on hormone release by altering the activity of a cyclic AMP-dependent protein kinase in islet cells.
mesh_terms: D000818:Animals; D001120:Arginine / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D003981:Diazoxide / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D007930:Leucine / Q000494:pharmacology; D008297:Male; D010759:Phosphorus Isotopes; D010770:Phosphotransferases / Q000378:metabolism*; D011494:Protein Kinases / Q000378:metabolism; D051381:Rats; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors; D014044:Tolbutamide / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology; D014993:Xylitol / Q000494:pharmacology
chemical_list: D007328:Insulin; D010759:Phosphorus Isotopes; D014970:Xanthines; D002110:Caffeine; D005934:Glucagon; D001120:Arginine; D014044:Tolbutamide; D013806:Theophylline; D000242:Cyclic AMP; D010770:Phosphotransferases; D011494:Protein Kinases; D007930:Leucine; D003981:Diazoxide; D005905:Glyburide; D014993:Xylitol; D004837:Epinephrine